In addition, the difference remained significant in eight out of these nine subgroups and marginally significant in grade IV glioma after taking into account age, gender, histology, IDH mutation status, MGMT methylation status, and co-deletion of 1p and 19q (Figures 3B, S12; Log-rank test, P < 0.05). This evidence concerns the gene MGMT and central nervous system cancer.